Bausch Health Companies Inc. Effective Income Tax Rate Reconciliation, Tax Contingency, Amount
Bausch Health Companies Inc. (BHC) reported Effective Income Tax Rate Reconciliation, Tax Contingency, Amount of -$2.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationTaxContingencies · last filed 2026-07-30
- Bausch Health Companies Inc. effective income tax rate reconciliation, tax contingency, amount for the quarter ending 2026-06-30 was -$6.00M.
- Bausch Health Companies Inc. effective income tax rate reconciliation, tax contingency, amount for the quarter ending 2026-03-31 was $4.00M, a 33.33% decline year-over-year.
- Bausch Health Companies Inc. effective income tax rate reconciliation, tax contingency, amount for the quarter ending 2025-12-31 was -$59.00M.
- Bausch Health Companies Inc. effective income tax rate reconciliation, tax contingency, amount for the quarter ending 2025-09-30 was $31.00M.
- Bausch Health Companies Inc. effective income tax rate reconciliation, tax contingency, amount for fiscal 2025 was -$47.00M.
| Period end | Effective Income Tax Rate Reconciliation, Tax Contingency, Amount 3 month | Effective Income Tax Rate Reconciliation, Tax Contingency, Amount 3 month as first filed | Effective Income Tax Rate Reconciliation, Tax Contingency, Amount 6 month | Effective Income Tax Rate Reconciliation, Tax Contingency, Amount 6 month as first filed | Effective Income Tax Rate Reconciliation, Tax Contingency, Amount 9 month | Effective Income Tax Rate Reconciliation, Tax Contingency, Amount 9 month as first filed | Effective Income Tax Rate Reconciliation, Tax Contingency, Amount 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$6.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | -$2.00M 10-Q · filed 2026-07-30 | -$61.00M derived: sum of 3 quarters · filed 2026-07-30 | -$30.00M derived: sum of 4 quarters · filed 2026-07-30 | |||
| 2026-03-31 | $4.00M 10-Q · filed 2026-04-30 | -$55.00M derived: sum of 2 quarters · filed 2026-04-30 | -$24.00M derived: sum of 3 quarters · filed 2026-04-30 | -$49.00M derived: sum of 4 quarters · filed 2026-07-30 | |||
| 2025-12-31 | -$59.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | -$28.00M derived: sum of 2 quarters · filed 2026-02-19 | -$53.00M derived: sum of 3 quarters · filed 2026-07-30 | -$47.00M 10-K · filed 2026-02-19 | |||
| 2025-09-30 | $31.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $6.00M derived: sum of 2 quarters · filed 2026-07-30 | $12.00M 10-Q · filed 2025-10-30 | ||||
| 2025-06-30 | -$25.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | -$19.00M 10-Q · filed 2026-07-30 | $10.00M 10-Q · filed 2025-07-31 | ||||
| 2025-03-31 | $6.00M 10-Q · filed 2026-04-30 | -$6.00M 10-Q · filed 2025-05-01 | |||||
| 2024-09-30 | -$5.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $29.00M derived: sum of 2 quarters · filed 2025-10-30 | $7.00M 10-Q · filed 2025-10-30 | -$7.00M 10-Q · filed 2024-10-31 | |||
| 2024-06-30 | $34.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | $12.00M 10-Q · filed 2025-07-31 | -$12.00M 10-Q · filed 2024-08-01 | ||||
| 2024-03-31 | -$22.00M 10-Q · filed 2025-05-01 | ||||||
| 2023-09-30 | $6.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $9.00M derived: sum of 2 quarters · filed 2024-10-31 | $27.00M 10-Q · filed 2024-10-31 | ||||
| 2023-06-30 | $3.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $21.00M 10-Q · filed 2024-08-01 | -$21.00M 10-Q · filed 2023-08-03 | ||||
| 2023-03-31 | $18.00M 10-Q · filed 2024-05-02 | ||||||
| 2022-09-30 | $2.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$1.00M derived: sum of 2 quarters · filed 2023-11-02 | -$37.00M 10-Q · filed 2023-11-02 | ||||
| 2022-06-30 | -$3.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$39.00M 10-Q · filed 2023-08-03 | |||||
| 2022-03-31 | -$36.00M 10-Q · filed 2023-05-04 | ||||||
| 2021-09-30 | $11.00M 10-Q · filed 2022-11-03 | ||||||
| 2021-03-31 | $3.00M 10-Q · filed 2022-05-10 | ||||||
| 2020-09-30 | $2.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | $0.00 derived: sum of 2 quarters · filed 2021-11-02 | -$10.00M 10-Q · filed 2021-11-02 | ||||
| 2020-06-30 | -$2.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | -$12.00M 10-Q · filed 2021-08-03 | |||||
| 2020-03-31 | -$10.00M 10-Q · filed 2021-05-04 | ||||||
| 2019-09-30 | -$3.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-03 | $5.00M derived: sum of 2 quarters · filed 2020-11-03 | $1.00M 10-Q · filed 2020-11-03 | ||||
| 2019-06-30 | $8.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $4.00M 10-Q · filed 2020-08-06 | |||||
| 2019-03-31 | -$4.00M 10-Q · filed 2020-05-07 | ||||||
| 2018-06-30 | -$55.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | -$57.00M 10-Q · filed 2019-08-06 | |||||
| 2018-03-31 | -$2.00M 10-Q · filed 2019-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |